The Potential Applications of Tregs in Organ Transplantation
DOI:
https://doi.org/10.54097/wbp15d90Keywords:
Organ transplantation, Tregs, Nanodelivery.Abstract
Treating patients with end-stage organ failure is ideally achieved through organ transplantation, but long-term reliance on non-specific immunosuppressants post-operatively easily leads to systemic toxicity and chronic graft rejection. In recent years, inducing specific immune tolerance using regulatory T cells (Tregs) has become a research hotspot, but the instability of Treg function in vivo and the lack of precise targeting remain unresolved research gaps. This article systematically analyzes the mechanism of action of Tregs in controlling organ transplant immune rejection, and explores their isolation and purification standards and cutting-edge infusion protocols. Simultaneously, it focuses on the innovative application of targeted nanodelivery technology (such as targeting the CD248 biomarker) to optimize Treg expression. The results show that precise targeted intervention can significantly increase the number of Treg cells in the graft, prolong the survival time of the allogeneic organ, and effectively reduce dependence on traditional immunosuppressive drugs. This analysis provides valuable reference for improving the prognosis of transplant patients using specific cell therapy. Although current challenges such as limited clinical research samples and difficulties in in vivo tracking remain unresolved, it is believed that future research will further explore targeted biomarkers and the timing of administration, comprehensively promoting the clinical translation of Treg therapy.
Downloads
References
[1] Juneja T, Kazmi M, Mellace M, Saidi RF. Utilization of Treg Cells in Solid Organ Transplantation. Frontiers in immunology. 2022;13:746889. DOI: https://doi.org/10.3389/fimmu.2022.746889
[2] Husain I, Luo X. Novel Approaches to Immunomodulation for Solid Organ Transplantation. Annual review of medicine. 2024;75:369-380. DOI: https://doi.org/10.1146/annurev-med-050522-034012
[3] Fortunato M, Morali K, Passeri L, Gregori S. Regulatory Cell Therapy in Organ Transplantation: Achievements and Open Questions. Frontiers in immunology. 2021;12:641596. DOI: https://doi.org/10.3389/fimmu.2021.641596
[4] OhkuraN,KitagawaY,SakaguchiS. Development and Maintenance of Regulatory T Cells. Immunity. 2013;38(3):414–423. DOI: https://doi.org/10.1016/j.immuni.2013.03.002
[5] Roncarolo MG, Gregori S, Bacchetta R, Battaglia M, Gagliani N. The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases. Immunity. 2018;49(6):1004-1019. DOI: https://doi.org/10.1016/j.immuni.2018.12.001
[6] Sato Y, Passerini L, Piening BD, Uyeda MJ, Goodwin M, Gregori S, Snyder MP, Bertaina A, Roncarolo MG, Bacchetta R. Human-engineered Treg-like cells suppress FOXP3-deficient T cells but preserve adaptive immune responses in vivo. Clinical & translational immunology. 2020;9(11):e1214. DOI: https://doi.org/10.1002/cti2.1214
[7] Safinia N, Grageda N, Scottà C, Thirkell S, Fry LJ, Vaikunthanathan T, Lechler RI, Lombardi G. Cell Therapy in Organ Transplantation: Our Experience on the Clinical Translation of Regulatory T Cells. Frontiers in immunology. 2018;9:354. DOI: https://doi.org/10.3389/fimmu.2018.00354
[8] Romano M, Fanelli G, Albany CJ, Giganti G, Lombardi G. Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity. Frontiers in immunology. 2019;10:43. DOI: https://doi.org/10.3389/fimmu.2019.00043
[9] Sánchez-Fueyo A, Whitehouse G, Grageda N, Cramp ME, Lim TY, Romano M, Thirkell S, Lowe K, Fry L, Heward J, Kerr A, Ali J, Fisher C, Lewis G, Hope A, Kodela E, Lyne M, Farzaneh F, Kordasti S, Rebollo-Mesa I, Jose Lozano J, Safinia N, Heaton N, Lechler R, Martínez-Llordella M, Lombardi G. Applicability, safety, and biological activity of regulatory T cell therapy in liver transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2020;20(4):1125-1136. DOI: https://doi.org/10.1111/ajt.15700
[10] Sato T, Takeda N. The roles of HIF-1α signaling in cardiovascular diseases. Journal of cardiology. 2023;81(2):202-208. DOI: https://doi.org/10.1016/j.jjcc.2022.09.002
[11] Sumida TS, Cheru NT, Hafler DA. The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases. Nature reviews. Immunology. 2024;24(7):503-517. DOI: https://doi.org/10.1038/s41577-024-00994-x
[12] Lu T, Song H, He L, Hu Z, Li Y, Xu C, Liu S, Jiang J, Zhou Y, Li Z, Li Z, Zhang K, Ma S, Qi R, Han S, Shi C, Wen W, Han D, Qin W. Targeted Expansion of Treg Cells to Induce Immune Tolerance after Kidney Transplantation. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2026;13(1):e07943. DOI: https://doi.org/10.1002/advs.202507943
[13] McCallion O, Cross AR, Brook MO, Hennessy C, Ferreira R, Trzupek D, Mulley WR, Kumar S, Soares M, Roberts IS, Friend PJ, Lombardi G, Wood KJ, Harden PN, Hester J, Issa F. Regulatory T cell therapy is associated with distinct immune regulatory lymphocytic infiltrates in kidney transplants. Med (New York, N.Y.). 2025;6(5):100561. DOI: https://doi.org/10.1016/j.medj.2024.11.014
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

